You are here
- Home
- Drug Products
- All Drug Products
A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
- Disease
- asthma
- Drug Name
- Symbicort
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Dec 12, 2011
- Study Name
- D5896C00027
- Study Id
- D5896C00027
- ClinicalTrials.gov ID
- NCT01444430
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
